Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:10283 |
Name | prostate cancer |
Definition | A male reproductive organ cancer that is located_in the prostate. |
Source | DiseaseOntology.org |
Alt Ids | DOID:514 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00670046 | Phase II | Valproic acid | Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer | Terminated | USA | 0 |
NCT00892736 | Phase I | Veliparib | Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy | Completed | USA | 0 |
NCT00942331 | Phase III | Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | Completed | USA | 1 |
NCT01254864 | Phase II | Abiraterone + Sunitinib Abiraterone + Dasatinib | Maximum Androgen Depletion | Completed | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01436968 | Phase III | Valacyclovir AdV-tk + Valacyclovir | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03) | Active, not recruiting | USA | 1 |
NCT01480154 | Phase I | Hydroxychloroquine + MK2206 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01517802 | Phase III | Abiraterone | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | Completed | USA | SWE | GBR | ESP | DEU | BEL | AUS | 0 |
NCT01530984 | Phase II | Sargramostim Ipilimumab | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | Withdrawn | USA | 0 |
NCT01540526 | Phase I | Axitinib | Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib | Completed | USA | 0 |
NCT01543776 | Phase II | Abiraterone | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | Completed | USA | 1 |
NCT01553188 | Phase II | Prednisone Abiraterone Trebananib | AMG 386 and Abiraterone for Advanced Prostate Cancer | Completed | USA | 0 |
NCT01576172 | Phase II | Abiraterone + Prednisone Abiraterone + Prednisone + Veliparib | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01620593 | Phase II | Metformin | Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer | Completed | USA | 0 |
NCT01674270 | Phase II | Bicalutamide Degarelix | Degarelix Neo-Adjuvant Radical Prostatectomy Trial | Completed | CAN | 0 |
NCT01683994 | Phase I | Cabozantinib + Docetaxel | Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer | Completed | USA | 0 |
NCT01685125 | Phase II | Dasatinib Abiraterone | Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Unknown status | USA | 0 |
NCT01715285 | Phase III | Abiraterone + Prednisone | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | Completed | TUR | SWE | SVK | ROU | POL | NZL | NLD | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 11 |
NCT01717053 | Phase II | Leuprolide Abiraterone Prednisone Goserelin | Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer | Completed | USA | 0 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01741753 | Phase I | Abiraterone + Buparlisib + Prednisone | BKM120+Abiraterone Acetate for Metastatic CRPC | Terminated | USA | 0 |
NCT01751451 | Phase II | Abiraterone Degarelix | 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy | Completed | USA | 0 |
NCT01809691 | Phase III | Orteronel Bicalutamide | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01818986 | Phase II | Sipuleucel-T | Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) | Completed | USA | 0 |
NCT01828476 | Phase II | Hydroxychloroquine Abiraterone + Navitoclax | Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | Terminated | USA | 0 |
NCT01834651 | Phase II | Cabozantinib | A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | Completed | USA | 0 |
NCT01864096 | Phase III | Metformin | The Metformin Active Surveillance Trial (MAST) Study | Active, not recruiting | CAN | 0 |
NCT01867333 | Phase II | PROSTVAC-F-TRICOM Enzalutamide | Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | Completed | USA | 0 |
NCT01875250 | Phase II | Enzalutamide + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer | Completed | USA | 0 |
NCT01884285 | Phase I | AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib | AZD8186 First Time In Patient Ascending Dose Study | Completed | USA | GBR | ESP | CAN | 0 |
NCT01913106 | Phase Ib/II | AdV-tk + Valacyclovir | HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer | Recruiting | USA | 0 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01972217 | Phase II | Prednisone Abiraterone Olaparib | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer | Completed | USA | POL | NLD | ITA | GBR | FRA | ESP | CZE | CAN | BEL | 1 |
NCT01989546 | Phase Ib/II | Talazoparib | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | Completed | USA | 0 |
NCT01990196 | Phase II | Dasatinib Trametinib Degarelix + Enzalutamide | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01994590 | Phase II | Dovitinib | Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Terminated | USA | 0 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02012296 | Phase Ib/II | Mifepristone Enzalutamide | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | Completed | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02020070 | Phase II | Ipilimumab Degarelix | Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | Active, not recruiting | USA | 0 |
NCT02028988 | Phase II | Enzalutamide | Enzalutamide + External Beam Rt For Prostate | Completed | USA | 0 |
NCT02043665 | Phase I | Coxsackievirus A21 | Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) | Completed | USA | GBR | AUS | 0 |
NCT02059213 | Phase II | Goserelin Palbociclib Bicalutamide Leuprolide | A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer | Completed | USA | 0 |
NCT02091531 | Phase II | Sapanisertib | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | Completed | USA | 0 |
NCT02115828 | Phase I | Vismodegib | A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy | Completed | USA | 0 |
NCT02159950 | Phase II | Sipuleucel-T Tasquinimod | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02218606 | Phase II | Cabazitaxel Abiraterone + Prednisone | Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | Completed | USA | 0 |
NCT02234921 | Phase I | Cyclophosphamide | Pilot Study of DRibble Vaccine for Prostate Cancer Patients | Completed | USA | 0 |
NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
NCT02265536 | Phase I | LY3022855 | A Study of LY3022855 In Participants With Breast or Prostate Cancer | Completed | USA | 0 |
NCT02278185 | Phase II | Goserelin Degarelix Histrelin acetate Triptorelin Leuprolide Enzalutamide | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02279862 | Phase II | Ipilimumab | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT02312557 | Phase II | Enzalutamide + Pembrolizumab | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | Active, not recruiting | USA | 0 |
NCT02325557 | Phase Ib/II | Pembrolizumab ADXS31-142 | ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046 | Completed | USA | 0 |
NCT02339168 | Phase I | Enzalutamide + Metformin | Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02366494 | Phase I | Leuprolide Goserelin Triptorelin Bicalutamide Docetaxel | Micro RNAs to Predict Response to Androgen Deprivation Therapy | Completed | USA | 0 |
NCT02403505 | Phase II | Enzalutamide Abiraterone Prednisone Degarelix | Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms | Active, not recruiting | USA | 0 |
NCT02420652 | Phase II | Metformin | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy | Terminated | USA | 0 |
NCT02429193 | Phase II | Enzalutamide Abiraterone + Prednisone | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P) | Completed | CAN | 0 |
NCT02430480 | Phase II | Goserelin | Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02438007 | Phase III | Galeterone Enzalutamide | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT02452008 | Phase II | Galunisertib Enzalutamide | Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02489357 | Phase I | Degarelix Pembrolizumab | Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer | Completed | USA | 0 |
NCT02494921 | Phase Ib/II | Docetaxel + Filgrastim + Prednisone + Ribociclib | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | Completed | USA | 0 |
NCT02507570 | Phase II | Enzalutamide Radium Ra 223 dichloride | Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis | Completed | USA | 0 |
NCT02522715 | Phase Ib/II | Cabazitaxel + Enzalutamide Prednisone | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02531516 | Phase III | Abiraterone + Apalutamide + Prednisone Bicalutamide | An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | ARG | 7 |
NCT02555189 | Phase Ib/II | Ribociclib Enzalutamide | Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression | Completed | USA | 0 |
NCT02566772 | Phase I | TAS3681 | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | Completed | USA | GBR | FRA | ESP | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | DNK | 0 |
NCT02594072 | Phase I | Goserelin | Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT) | Active, not recruiting | CAN | 0 |
NCT02607228 | Phase Ib/II | Enzalutamide Exemestane + GS-5829 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT02614859 | Phase II | Bicalutamide Metformin | Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients | Completed | USA | 0 |
NCT02616185 | Phase I | PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab | A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) | Terminated | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT02663908 | Phase III | Degarelix Leuprolide | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease | Terminated | USA | SVK | POL | GRC | GBR | FRA | FIN | DEU | CZE | CAN | 2 |
NCT02698176 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) | Terminated | 0 | |
NCT02705469 | Phase I | ZEN-3694 | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02711956 | Phase I | Enzalutamide + ZEN-3694 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02721433 | FDA approved | Denosumab + pamidronate + Zoledronic acid | 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) | Completed | CAN | 0 |
NCT02744287 | Phase Ib/II | BPX-601 + Rimiducid | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | Suspended | USA | 0 |
NCT02766478 | Phase II | Genistein | Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer | Terminated | USA | 0 |
NCT02796898 | Phase Ib/II | SM88 | Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer | Completed | USA | 0 |
NCT02807805 | Phase II | Abiraterone + Niclosamide + Prednisone | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02833883 | Phase I | CC-115 + Enzalutamide | Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02854436 | Phase II | Niraparib | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | Completed | USA | SWE | NLD | ISR | GBR | FRA | ESP | DNK | CAN | BRA | BEL | AUS | 3 |
NCT02881242 | Phase II | Trametinib | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02887976 | Phase III | Abiraterone + Methylprednisolone | Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 | Completed | USA | 0 |
NCT02900651 | Phase Ib/II | MAK683 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Terminated | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT02924766 | Phase I | Apalutamide + Niraparib | A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE) | Completed | USA | CAN | 0 |
NCT02933255 | Phase Ib/II | Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer | Completed | USA | 0 |
NCT02935205 | Phase Ib/II | Enzalutamide + Indomethacin | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT02950064 | Phase I | BTP-114 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | Unknown status | USA | 0 |
NCT02960022 | Phase II | Abiraterone + Enzalutamide + Prednisone Enzalutamide | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NZL | NOR | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 13 |
NCT02966587 | Phase II | Durvalumab | Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT02972060 | Phase II | Triptorelin Leuprolide Degarelix Goserelin Darolutamide | ODM-201 vs Androgen Deprivation Therapy in Hormone naive Prostate Cancer | Active, not recruiting | ITA | FRA | ESP | BEL | 0 |
NCT02985957 | Phase II | Ipilimumab + Nivolumab | A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | POL | ITA | FRA | ESP | DNK | DEU | CAN | AUT | AUS | 0 |
NCT02987543 | Phase III | Olaparib Enzalutamide Abiraterone | Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | Completed | USA | TUR | SWE | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BRA | AUT | AUS | ARG | 3 |
NCT03016741 | FDA approved | Enzalutamide Abiraterone + Prednisone | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | Unknown status | USA | 0 |
NCT03067051 | Phase I | Verteporfin | Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System | Recruiting | USA | SWE | GBR | CAN | 0 |
NCT03088124 | Phase II | Apalutamide | Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (PC-ARN) | Unknown status | FRA | 0 |
NCT03089203 | Phase I | CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine | CART-PSMA-TGFbetaRDN Cells for Castrate-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03098160 | Phase I | Evofosfamide + Ipilimumab | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | Unknown status | USA | 0 |
NCT03102606 | Phase II | Plinabulin Pegfilgrastim | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) | Completed | USA | 3 |
NCT03120832 | Phase I | PAN-301-1 | Phase 1 Trial of PAN-301-1 in Cancer Patients | Completed | USA | 0 |
NCT03123978 | Phase I | Enzalutamide + Niclosamide | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT03141671 | Phase II | Bicalutamide + Gonadorelin Abiraterone + Apalutamide + Gonadorelin + Prednisone | Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | Active, not recruiting | USA | 0 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | AUS | 0 |
NCT03179410 | Phase II | Avelumab | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC) | Completed | USA | 0 |
NCT03188965 | Phase I | Elimusertib | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CHE | CAN | 3 |
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT03217747 | Phase Ib/II | Avelumab + PF-04518600 + Utomilumab Avelumab + Utomilumab Avelumab + PF-04518600 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | Active, not recruiting | USA | 0 |
NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
NCT03311555 | Phase II | Apalutamide + Docetaxel | A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) | Completed | USA | 0 |
NCT03315871 | Phase II | Bintrafusp alfa + CV301 + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | Combination Immunotherapy in Biochemically Recurrent Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03325127 | Phase I | Abiraterone + Enzalutamide + Radium Ra 223 dichloride | Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study | Withdrawn | 0 | |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | HUN | GBR | DNK | CAN | BEL | AUS | 2 |
NCT03333616 | Phase II | Ipilimumab + Nivolumab | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Active, not recruiting | USA | 0 |
NCT03344211 | Phase II | Enzalutamide + Radium Ra 223 dichloride Enzalutamide | Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03358563 | Phase I | Bicalutamide + Degarelix + Docetaxel | Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer | Completed | USA | 0 |
NCT03360006 | Phase I | ABBV-744 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer | Terminated | USA | 0 |
NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |
NCT03363893 | Phase Ib/II | Samuraciclib Fulvestrant + Samuraciclib | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03367819 | Phase Ib/II | Isatuximab Cemiplimab + Isatuximab | Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies | Terminated | USA | ITA | GBR | FRA | 1 |
NCT03409458 | Phase Ib/II | Avelumab + Imifoplatin | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) | Completed | USA | CHE | 0 |
NCT03418324 | Phase II | Abiraterone + Carotuximab Carotuximab + Enzalutamide | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | Completed | USA | 0 |
NCT03436485 | Phase Ib/II | ODM-208 | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) | Active, not recruiting | USA | GBR | FRA | FIN | 0 |
NCT03450109 | Phase I | LY01005 Goserelin | A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX) in Patients With Prostate Cancer | Completed | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | POL | ESP | BGR | 4 |
NCT03473925 | Phase II | Navarixin + Pembrolizumab | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | Completed | USA | ISR | CAN | AUS | 1 |
NCT03477864 | Phase I | Ipilimumab Cemiplimab + Ipilimumab Cemiplimab | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | Withdrawn | 0 | |
NCT03478904 | Phase I | Enzalutamide | Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer | Terminated | USA | 0 |
NCT03481816 | Phase I | ETBX-051 + ETBX-061 + ETBX-071 | Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines | Completed | USA | 0 |
NCT03493945 | Phase Ib/II | Bintrafusp alfa + Epacadostat + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + Nogapendekin alfa inbakicept | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). | Completed | USA | 0 |
NCT03507608 | Phase I | Flutamide | Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression | Active, not recruiting | USA | 0 |
NCT03511664 | Phase III | lutetium Lu 177 vipivotide tetraxetan | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION) | Completed | USA | SWE | NLD | GBR | FRA | DNK | DEU | CAN | BEL | 1 |
NCT03517969 | Phase II | Carboplatin + Docetaxel Berzosertib + Carboplatin | ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03518606 | Phase Ib/II | Durvalumab + Tremelimumab + Vinorelbine | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) | Active, not recruiting | FRA | 0 |
NCT03531827 | Phase II | Enzalutamide + NLG207 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | Terminated | USA | 0 |
NCT03543189 | Phase Ib/II | Nivolumab | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | Active, not recruiting | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03568656 | Phase Ib/II | Atezolizumab + CCS1477 CCS1477 CCS1477 + Olaparib CCS1477 + Darolutamide Abiraterone + CCS1477 CCS1477 + Enzalutamide | Study to Evaluate CCS1477 in Advanced Tumours | Recruiting | USA | SWE | NLD | GBR | FRA | ESP | 0 |
NCT03572478 | Phase Ib/II | Nivolumab + Rucaparib Nivolumab Rucaparib | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Terminated | USA | 0 |
NCT03575819 | Phase I | FOR46 | A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Completed | USA | 0 |
NCT03592264 | Phase Ib/II | OBI-3424 | This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer | Terminated | USA | 0 |
NCT03673787 | Phase Ib/II | Atezolizumab + Ipatasertib | A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP) | Unknown status | GBR | 0 |
NCT03674814 | Phase I | Enzalutamide + Relacorilant | Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03685591 | Phase I | PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03689699 | Phase II | BMS-986253 + Degarelix + Nivolumab Degarelix + Nivolumab | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | Active, not recruiting | USA | 0 |
NCT03709550 | Phase Ib/II | Decitabine + Enzalutamide | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT03751436 | Phase Ib/II | Enzalutamide + Venetoclax | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | Completed | USA | 0 |
NCT03761225 | Phase III | Docetaxel + Prednisone Docetaxel + Masitinib + Prednisone | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | Completed | ITA | FRA | CAN | 3 |
NCT03777982 | Phase III | Abiraterone + Apalutamide + Prednisone | A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | Terminated | USA | 0 |
NCT03784677 | Phase I | SOR-C13 | SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT03792841 | Phase I | AMG 160 + Pembrolizumab AMG 160 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC | Completed | USA | NLD | FRA | CAN | BEL | AUT | AUS | 3 |
NCT03799003 | Phase I | ASP1951 | A Study of ASP1951 in Subjects With Advanced Solid Tumors | Terminated | USA | CAN | 2 |
NCT03810105 | Phase II | Durvalumab + Olaparib | A Study of Olaparib and Durvalumab in Prostate Cancer | Terminated | USA | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03835533 | Phase I | CDX-301 + INO-5151 + Nivolumab CDX-301 + Nivolumab + Poly ICLC Nivolumab + NKTR-214 | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER) | Completed | USA | 0 |
NCT03850795 | Phase III | Enzalutamide HC-1119 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Terminated | USA | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | AUS | 1 |
NCT03860987 | Phase II | Abiraterone + Enzalutamide + Goserelin + Prednisone | Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03873805 | Phase I | Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR-T cells | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
NCT03899467 | Phase II | Proxalutamide | the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer | Completed | USA | 0 |
NCT03934840 | Phase II | Abiraterone + Cabazitaxel + Carboplatin + Prednisone | Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03951831 | Phase II | Cemiplimab + Degarelix + Docetaxel + Leuprolide | REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |
NCT04009967 | Phase II | Pembrolizumab | Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01) | Active, not recruiting | CAN | 0 |
NCT04019964 | Phase II | Nivolumab | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | Recruiting | USA | 0 |
NCT04030559 | Phase II | Niraparib | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | Recruiting | USA | 0 |
NCT04038502 | Phase II | Olaparib Carboplatin | Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA) | Recruiting | USA | 0 |
NCT04052204 | Phase II | Avelumab + NKTR-214 Avelumab + NKTR-214 + Talazoparib Avelumab + Enzalutamide + NKTR-214 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | Terminated | USA | POL | ESP | BEL | 0 |
NCT04052971 | Phase Ib/II | ABN401 | To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation | Recruiting | AUS | 1 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04071236 | Phase Ib/II | Peposertib + Radium Ra 223 dichloride Radium Ra 223 dichloride Avelumab + Peposertib + Radium Ra 223 dichloride | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | Recruiting | USA | 0 |
NCT04087174 | Phase I | Abiraterone + Capivasertib Capivasertib + Enzalutamide | A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | Completed | USA | ESP | 0 |
NCT04089553 | Phase II | AZD4635 + Durvalumab AZD4635 + Oleclumab | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | Completed | USA | 0 |
NCT04095273 | Phase I | Elimusertib + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Completed | USA | GBR | ESP | DEU | CHE | 0 |
NCT04104607 | Phase I | CC-1 | the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (PSMAxCD3) | Recruiting | DEU | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04143789 | Phase Ib/II | AP-002 | Evaluation of AP-002 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT04145375 | Phase Ib/II | Enzalutamide + ZEN-3694 | Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol | Enrolling by invitation | USA | 0 |
NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | GBR | AUS | 0 |
NCT04157517 | Phase I | TAK-573 | A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study | Completed | USA | AUS | 0 |
NCT04159896 | Phase II | CEP-11981 + Nivolumab | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |
NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Active, not recruiting | FRA | 0 |
NCT04182516 | Phase I | NMS-03305293 | Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors | Terminated | USA | ITA | GBR | BGR | 1 |
NCT04207255 | Phase II | ABC294640 + Enzalutamide ABC294640 + Abiraterone | Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | Completed | USA | 0 |
NCT04221542 | Phase I | AMG 509 + Dexamethasone | Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ESP | DEU | CHE | AUS | 5 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04249947 | Phase I | P-PSMA-101 CAR-T cells Rimiducid | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | USA | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04253262 | Phase Ib/II | Copanlisib + Rucaparib | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04267887 | Phase II | Abiraterone + Apalutamide + Prednisone | Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04276376 | Phase II | Atezolizumab + Rucaparib | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) | Suspended | FRA | 0 |
NCT04337099 | Expanded access | Tempol | A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer | Available | USA | 0 |
NCT04337580 | Phase II | Cabazitaxel + Omeprazole Docetaxel + Omeprazole | Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (FASN) | Recruiting | USA | 0 |
NCT04343885 | Phase II | Docetaxel Docetaxel + lutetium Lu 177 vipivotide tetraxetan | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA) | Active, not recruiting | AUS | 0 |
NCT04367675 | Phase I | INO-5401 INO-5401 + INO-9012 | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Recruiting | USA | 0 |
NCT04381832 | Phase Ib/II | Enzalutamide + Etrumadenant + Zimberelimab Docetaxel + Etrumadenant + Zimberelimab AB680 + Etrumadenant + Zimberelimab AB680 + Etrumadenant Enzalutamide Docetaxel Etrumadenant + Zimberelimab | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6) | Completed | USA | CAN | 0 |
NCT04408924 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1) | Completed | USA | FRA | ESP | 0 |
NCT04419402 | Phase II | Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Enzalutamide | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p) | Active, not recruiting | AUS | 0 |
NCT04421222 | Phase I | EPI-7386 | Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer (EPI-7386) | Active, not recruiting | USA | CAN | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Completed | USA | AUS | 3 |
NCT04477512 | Phase I | Abiraterone + Cabozantinib + Nivolumab + Prednisone | Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) | Active, not recruiting | USA | 0 |
NCT04478279 | Phase Ib/II | ST-101 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT04484818 | Phase III | Goserelin Leuprolide Darolutamide + Leuprolide Darolutamide + Triptorelin Triptorelin Darolutamide + Goserelin | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | Active, not recruiting | USA | 0 |
NCT04550494 | Phase II | Talazoparib | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Recruiting | USA | 0 |
NCT04564027 | Phase II | Ceralasertib | A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | Active, not recruiting | USA | FRA | ESP | 0 |
NCT04565496 | Phase II | Pembrolizumab | Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients (PEM-PRO) | Unknown status | ITA | 0 |
NCT04575766 | Phase I | FT-7051 | A Study of FT-7051 in Men With MCRPC | Terminated | USA | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT04585932 | Phase II | Apalutamide + Degarelix Apalutamide + Leuprolide | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | Withdrawn | USA | 0 |
NCT04606446 | Phase I | PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) | Recruiting | USA | AUS | 3 |
NCT04633252 | Phase Ib/II | Docetaxel + NHS-IL12 Bintrafusp alfa + Degarelix + Docetaxel + NHS-IL12 + Prednisone Degarelix + Docetaxel + NHS-IL12 + Prednisone Bintrafusp alfa + Docetaxel + NHS-IL12 | Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT04663997 | Phase II | Docetaxel lutetium Lu 177 vipivotide tetraxetan | 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | Active, not recruiting | CAN | 0 |
NCT04676334 | Phase III | Rucaparib | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) | Completed | POL | ITA | ISR | GBR | CAN | 1 |
NCT04677855 | Phase I | Dutasteride + PCUR-101 PCUR-101 Abiraterone + PCUR-101 + Prednisone | Study of PCUR-101 in Combination With ADT in Patients With mCRPC | Terminated | USA | AUS | 0 |
NCT04703920 | Phase I | Belinostat + Talazoparib | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04709276 | Phase II | Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) | Recruiting | USA | 0 |
NCT04729114 | Phase Ib/II | PRL-02 | Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer | Recruiting | USA | 0 |
NCT04737109 | Phase Ib/II | Darolutamide + Ipatasertib | Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer | Terminated | USA | 0 |
NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |
NCT04821622 | Phase III | Enzalutamide Enzalutamide + Talazoparib | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Active, not recruiting | USA | TUR | SVK | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BGR | BEL | AUS | ARG | 9 |
NCT04839991 | Phase I | CB307 | Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) | Recruiting | USA | NLD | GBR | ESP | 0 |
NCT04843319 | Phase Ib/II | VERU-100 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer (VERU-100) | Terminated | USA | 0 |
NCT04846478 | Phase I | Talazoparib + Tazemetostat | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | Active, not recruiting | USA | 0 |
NCT04848337 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC) | Recruiting | USA | 0 |
NCT04876755 | Phase II | Tempol | MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer | Unknown status | USA | 0 |
NCT04890613 | Phase I | CX-5461 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Recruiting | USA | CAN | 0 |
NCT04925648 | Phase II | Darolutamide + Dasatinib Dasatinib | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO) | Recruiting | AUS | 0 |
NCT04943536 | Phase I | Biolen | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer (Biolen + RT) | Recruiting | USA | 0 |
NCT04957290 | Phase Ib/II | NOX66 | A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | Terminated | USA | 0 |
NCT04969315 | Phase Ib/II | TT-10 | TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | Active, not recruiting | USA | 0 |
NCT04970992 | Phase I | DZ-002 | A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | Recruiting | USA | 0 |
NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Active, not recruiting | USA | GBR | ESP | 0 |
NCT04986423 | Phase II | Enzalutamide + ZEN-3694 Enzalutamide | ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 1 |
NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Recruiting | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Recruiting | USA | 0 |
NCT05036226 | Phase Ib/II | Hydroxychloroquine + Metformin + Sirolimus Dasatinib + Hydroxychloroquine + Metformin + Nelfinavir + Sirolimus Hydroxychloroquine + Metformin + Nelfinavir + Sirolimus Dasatinib + Hydroxychloroquine + Metformin + Sirolimus | COAST Therapy in Advanced Solid Tumors and Prostate Cancer (COAST) | Recruiting | USA | 0 |
NCT05037500 | Phase I | Decitabine and Cedazuridine + Enzalutamide | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05084859 | Phase I | Abiraterone + Prednisone + SM08502 Fluorouracil + Irinotecan + Leucovorin + Panitumumab + SM08502 Docetaxel + SM08502 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | Terminated | USA | AUS | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05104515 | Phase I | OVM-200 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | Recruiting | GBR | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05113537 | Phase Ib/II | Abemaciclib + lutetium Lu 177 vipivotide tetraxetan | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT) | Recruiting | USA | 0 |
NCT05150236 | Phase II | Ipilimumab + lutetium Lu 177 vipivotide tetraxetan + Nivolumab lutetium Lu 177 vipivotide tetraxetan Nivolumab | 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION) | Active, not recruiting | AUS | 0 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT05169112 | Phase III | Leuprolide | Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | Recruiting | CAN | 0 |
NCT05177770 | Phase II | Etrumadenant + SRF617 + Zimberelimab | Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | Terminated | USA | CAN | 0 |
NCT05189457 | Phase II | Docetaxel + Triptorelin Degarelix + Enzalutamide Enzalutamide + Triptorelin Docetaxel + Leuprolide Docetaxel + Relugolix Docetaxel + Goserelin Degarelix + Docetaxel Enzalutamide + Relugolix Enzalutamide + Goserelin Abiraterone + Leuprolide Docetaxel + Tislelizumab Enzalutamide + Leuprolide Abiraterone + Goserelin Abiraterone + Triptorelin Abiraterone + Degarelix Abiraterone + Relugolix | First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT05191017 | Phase Ib/II | Enzalutamide + NUV-422 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | Withdrawn | USA | 0 |
NCT05191680 | Phase III | Apalutamide | TherApeutics in Early ProState Cancer (TAPS02) | Recruiting | GBR | 0 |
NCT05241613 | Phase I | AC176 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |
NCT05252390 | Phase Ib/II | NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Active, not recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
NCT05272709 | Phase Ib/II | TT-702 | TT-702 in Patients With Advanced Solid Tumours. (CURATE) | Recruiting | GBR | 0 |
NCT05276492 | Phase I | Abiraterone + Prednisone | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. | Active, not recruiting | USA | 0 |
NCT05293496 | Phase I | MGC018 + MGD019 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05307874 | Phase Ib/II | Aldesleukin + ICT01 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) | Recruiting | FRA | 0 |
NCT05346848 | Phase II | Darolutamide | A Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer (DARIUS) | Recruiting | FRA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05361798 | Phase II | NHS-IL12 | T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy | Recruiting | USA | 0 |
NCT05361915 | Phase II | Abiraterone + Abivertinib | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | Suspended | USA | 0 |
NCT05367440 | Phase Ib/II | Darolutamide + Saruparib Abiraterone + Saruparib Enzalutamide + Saruparib | Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) | Recruiting | USA | ITA | GBR | AUS | 0 |
NCT05369000 | Phase Ib/II | LAVA-1207 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | NLD | ESP | 0 |
NCT05383079 | Phase Ib/II | Lutetium-177 PSMA-I&T | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study (AlphaBet) | Recruiting | AUS | 0 |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05413421 | Phase I | ORIC-944 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05415098 | Phase I | APG-5918 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05417594 | Phase Ib/II | AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | SWE | GBR | ESP | DEU | AUS | 1 |
NCT05420636 | Phase II | ORY-1001 + Paclitaxel | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | Recruiting | USA | 0 |
NCT05445882 | Phase II | Bintrafusp alfa + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT05458856 | Phase III | Triptorelin | Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate | Completed | NLD | LTU | FRA | ESP | DEU | CZE | BEL | 0 |
NCT05488548 | Phase I | NEO2734 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05534646 | Phase II | Apalutamide Apalutamide + Carotuximab | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05567679 | Phase I | Tazemetostat | A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer | Withdrawn | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05642780 | Phase II | Pembrolizumab + SKB264 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | Recruiting | USA | POL | CAN | BEL | AUS | 1 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Recruiting | USA | 0 |
NCT05679388 | Phase I | Relugolix Itraconazole + Relugolix Relugolix + Ritonavir | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients | Terminated | USA | 0 |
NCT05683964 | Phase I | Apalutamide Darolutamide Enzalutamide | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | Recruiting | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05726292 | Phase II | Enzalutamide Enzalutamide + Relacorilant | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | Recruiting | USA | 0 |
NCT05730712 | Phase II | Enzalutamide + Pertuzumab/trastuzumab/hyaluronidase-zzxf | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study | Recruiting | USA | 0 |
NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT05743621 | Phase I | Enzalutamide + TVB-2640 | Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05751941 | Phase II | Sipuleucel-T Abiraterone + Sipuleucel-T Apalutamide + Sipuleucel-T Enzalutamide + Sipuleucel-T | Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | Recruiting | USA | 0 |
NCT05762536 | Phase II | Docetaxel Cabazitaxel + Darolutamide Darolutamide + Docetaxel Cabazitaxel | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC (DAROTAXEL) | Recruiting | NLD | 0 |
NCT05781217 | Phase III | Bicalutamide + Triptorelin Bicalutamide + Leuprolide Bicalutamide + Goserelin | Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624 (URONCOR 06-24) | Recruiting | ESP | 0 |
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05790213 | Phase II | Apalutamide | Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer | Suspended | USA | 0 |
NCT05805371 | Phase I | Anti-PSCA(dCH2)BBz-CAR-T cells | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05806814 | Phase I | Sipuleucel-T | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer | Recruiting | USA | 0 |
NCT05807126 | Phase I | Hu5F9-G4 + Olaparib | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | Withdrawn | USA | 0 |
NCT05828082 | Phase II | M1774 | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | Recruiting | USA | 0 |
NCT05849298 | Phase II | lutetium Lu 177 vipivotide tetraxetan Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Darolutamide + lutetium Lu 177 vipivotide tetraxetan Apalutamide + lutetium Lu 177 vipivotide tetraxetan | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare) | Recruiting | USA | POL | NLD | ITA | FRA | ESP | CZE | CAN | 3 |
NCT05884398 | Phase III | Apalutamide | A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS) | Recruiting | USA | POL | FRA | DEU | CAN | BRA | AUS | 2 |
NCT05893381 | Phase II | PNT2002 | Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) (LUST) | Recruiting | ITA | 0 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05917860 | Phase I | Degarelix | Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA) | Recruiting | FIN | 0 |
NCT05932862 | Phase I | ISM3091 | First-in Human Phase I Study of ISM3091 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05938270 | Phase I | Darolutamide Darolutamide + Saruparib Saruparib | A Study to Investigate the Biological Effects of AZD5305, Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN) | Recruiting | USA | NLD | GBR | ESP | CAN | AUS | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT05983198 | Phase Ib/II | 225Ac-PSMA-R2 | A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy. | Recruiting | FRA | AUS | 0 |
NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05997615 | Phase Ib/II | AMX-500 | Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC) | Recruiting | GBR | ESP | AUS | 0 |
NCT06014502 | Phase I | IMGS-001 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06033001 | Expanded access | PNT2002 | Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Available | USA | 0 |
NCT06046040 | Phase I | TmPSMA-02 CAR-T cells | TmPSMA-02 in mCRPC | Recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06060587 | Phase II | Abiraterone Abiraterone + Docetaxel | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | Active, not recruiting | USA | 0 |
NCT06096870 | Phase II | Enzalutamide Enzalutamide + NHS-IL12 | Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy | Recruiting | USA | 0 |
NCT06111781 | Phase III | Relugolix | The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer | Recruiting | USA | 0 |
NCT06126731 | Phase Ib/II | Amoxicillin + Enzalutamide + Metronidazole Ciprofloxacin + Enzalutamide + Vancomycin | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | Recruiting | GBR | CHE | 0 |
NCT06129851 | Phase II | Relugolix | Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | Not yet recruiting | USA | 0 |
NCT06168487 | Phase I | Telmisartan | Telmisartan in Prostate Cancer | Recruiting | USA | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06200103 | FDA approved | lutetium Lu 177 vipivotide tetraxetan | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT06216249 | Phase II | lutetium Lu 177 vipivotide tetraxetan | Evaluation of a Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT06218667 | Phase Ib/II | Copanlisib + Degarelix | A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer | Withdrawn | 0 | |
NCT06220188 | Phase II | Lutetium-177 PSMA-I&T | PSMA-RLT in Biochemically Recurrent PCa | Recruiting | AUT | 0 |
NCT06228053 | Phase II | Enzalutamide + SX-682 | Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201) | Recruiting | USA | 0 |
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | AUS | 0 |
NCT06253130 | Phase Ib/II | IMP1734 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 2 |
NCT06259123 | Phase II | Lutetium-177 PSMA-I&T | Neoadjuvant PSMA-RLT in Oligometastatic PCa | Recruiting | AUT | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT06282588 | Phase II | Docetaxel Leuprolide Degarelix Goserelin Triptorelin Darolutamide | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) | Recruiting | BEL | 0 |
NCT06288113 | Phase II | lutetium Lu 177 vipivotide tetraxetan | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | Recruiting | USA | 0 |
NCT06343038 | Phase I | Lutetium-177 PSMA-I&T 161Tb-SibuDAB | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS) | Recruiting | CHE | 0 |
NCT06347705 | Phase II | 2141 V-11 | A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | Recruiting | USA | 0 |
NCT06378866 | Phase II | Degarelix Goserelin Darolutamide Relugolix Triptorelin Enzalutamide Histrelin acetate Abiraterone + Prednisone Leuprolide Apalutamide | Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE) | Recruiting | USA | 0 |
NCT06395753 | Phase II | Debio 4228 | A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer | Recruiting | USA | FRA | ESP | BEL | 0 |
NCT06397703 | Phase III | Leuprolide Degarelix Relugolix | ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | Recruiting | USA | 0 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06458712 | Phase I | DSB2455 | Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | Recruiting | ESP | 0 |
NCT06463457 | Phase II | Darolutamide + Relugolix | Comeback From Long coursE ADT With RElugolix and Darolutamide (CLEARED) | Recruiting | USA | 0 |
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | ESP | 1 |
NCT06526299 | Phase II | lutetium Lu 177 vipivotide tetraxetan | Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease | Not yet recruiting | USA | 0 |
NCT06545942 | Phase I | MOMA-313 + Olaparib MOMA-313 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT06582017 | Phase I | QXL138AM | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Recruiting | USA | 0 |
NCT06630325 | Phase II | Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | Not yet recruiting | USA | 0 |
NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |
NCT06636123 | Phase I | GZ17-6.02 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | Not yet recruiting | USA | 0 |
NCT06636682 | Phase II | FK-PC101 | FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | Recruiting | USA | 0 |